← Back to Screener
MeiraGTx Holdings plc Ordinary Shares (MGTX)
Price$9.00
Value ScoreD
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)0.51%
Price vs S&P 500 (4W)-8.34%
VGM Score52.36
Market Capitalization$833.49M
All Metrics
Book Value / Share (Quarterly)$0.04
P/TBV (Annual)7.10x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)72.27%
Cash Flow / Share (Quarterly)$0.05
Price vs S&P 500 (YTD)5.05%
Gross Margin (TTM)95.41%
Net Profit Margin (TTM)-151.12%
EPS (TTM)$-1.49
10-Day Avg Trading Volume0.80M
EPS Excl Extra (TTM)$-1.49
Revenue Growth (5Y)39.22%
EPS (Annual)$-1.42
ROI (Annual)-104.78%
Gross Margin (Annual)94.05%
Net Profit Margin (5Y Avg)-441.82%
Cash / Share (Quarterly)$0.88
Revenue Growth QoQ (YoY)-84.79%
ROA (Last FY)-46.72%
Revenue Growth TTM (YoY)131.13%
EBITD / Share (TTM)$-1.14
ROE (5Y Avg)-91.21%
Operating Margin (TTM)-131.89%
Cash Flow / Share (Annual)$-0.62
P/B Ratio281.58x
P/B Ratio (Quarterly)177.20x
Net Income / Employee (Annual)$-285,500
EV / Revenue (TTM)10.49x
Net Interest Coverage (TTM)-13.13x
ROA (TTM)-54.96%
EPS Incl Extra (Annual)$-1.42
Current Ratio (Annual)0.75x
Quick Ratio (Quarterly)0.51x
3-Month Avg Trading Volume0.68M
52-Week Price Return64.23%
Revenue / Employee (TTM)$199,400
Tangible BV / Share (Quarterly)$0.03
P/S Ratio (Annual)10.24x
Asset Turnover (Annual)0.33x
52-Week High$11.85
Operating Margin (5Y Avg)-505.07%
EPS Excl Extra (Annual)$-1.42
CapEx CAGR (5Y)-30.17%
Tangible BV CAGR (5Y)-18.82%
26-Week Price Return8.43%
Quick Ratio (Annual)0.70x
13-Week Price Return28.76%
Total Debt / Equity (Annual)1.08x
Current Ratio (Quarterly)0.55x
Enterprise Value$836.65M
Revenue / Share Growth (5Y)19.66%
Asset Turnover (TTM)0.36x
Book Value / Share Growth (5Y)-30.10%
Revenue / Employee (Annual)$203,500
Pretax Margin (Annual)-140.31%
Cash / Share (Annual)$0.81
3-Month Return Std Dev73.49%
Net Income / Employee (TTM)$-301,300
ROE (Last FY)-217.89%
Net Interest Coverage (Annual)-2.85x
EPS Basic Excl Extra (Annual)$-1.42
P/FCF (TTM)13.41x
Receivables Turnover (TTM)37.38x
EV / Free Cash Flow (TTM)201.36x
Total Debt / Equity (Quarterly)24.92x
EPS Incl Extra (TTM)$-1.49
Receivables Turnover (Annual)34.95x
ROI (TTM)-127.78%
P/S Ratio (TTM)10.45x
Pretax Margin (5Y Avg)-441.82%
Revenue / Share (Annual)$1.01
Tangible BV / Share (Annual)$0.85
Price vs S&P 500 (52W)39.87%
Year-to-Date Return13.21%
5-Day Price Return-8.16%
EPS Normalized (Annual)$-1.42
ROA (5Y Avg)-38.56%
Net Profit Margin (Annual)-140.31%
Month-to-Date Return-15.49%
Cash Flow / Share (TTM)$-2.29
EBITD / Share (Annual)$-1.31
Operating Margin (Annual)-130.20%
LT Debt / Equity (Annual)1.08x
P/CF (TTM)100.67x
ROI (5Y Avg)-56.13%
LT Debt / Equity (Quarterly)24.92x
EPS Basic Excl Extra (TTM)$-1.49
P/TBV (Quarterly)236.48x
P/B Ratio (Annual)7.02x
Inventory Turnover (TTM)25.16x
Pretax Margin (TTM)-151.12%
Book Value / Share (Annual)$0.87
Price vs S&P 500 (13W)20.50%
Beta1.31x
P/FCF (Annual)75.36x
Revenue / Share (TTM)$0.98
ROE (TTM)-315.61%
52-Week Low$5.24
vGradeD
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.57est. -0.41
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.21
4.21
4.21
4.21
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MGTXMeiraGTx Holdings plc Ordinary Shares | D | C | B | $9.00 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
MeiraGTx Holdings is a clinical-stage gene therapy company developing AAV-based treatments for genetic disorders affecting the eye, salivary gland, and central nervous system. Its pipeline includes programs such as AAV-CNGB3 and AAV-RPGR targeting inherited retinal dystrophies and other rare genetic conditions. The company operates across the United States, United Kingdom, and European Union.